Author:
Cantor Erica L,Shen Fei,Jiang Guanglong,Philips Santosh,Schneider Bryan P
Funder
Susan G. Komen for the Cure
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Chan, Y.-N. et al. Taxane-induced peripheral neuropathy: objective and subjective comparison between paclitaxel and docetaxel in patients with breast cancer. Clin. J. Oncol. 23, 494–501 (2019).
2. Kincaid, K., Boitano, T. K. L., Leath, C. A. & Straughn, J. M. Impact of paclitaxel versus docetaxel on neuropathy in ovarian cancer patients with diabetes. J. Clin. Oncol. 40, e17616. https://doi.org/10.1200/JCO.2022.40.16_suppl.e17616 (2022).
3. Trivedi, M. S. et al. Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714. J. Clin. Oncol. 41, 12003. https://doi.org/10.1200/JCO.2023.41.16_suppl.12003 (2023).
4. Sparano, J. A. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358, 1663–1671 (2008).
5. ECOG-ACRIN-EAZ171. Docetaxel or paclitaxel in reducing chemotherapy-induced peripheral neuropathy in African American patients with stage I-III breast cancer. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04001829 (2019).